Display options
Cite
Irawati D, Mamo JC, Dhaliwal SS, et al. Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome. Lipids Health Dis. 2016;15(1):169doi: 10.1186/s12944-016-0330-4.
Irawati, D., Mamo, J. C., Dhaliwal, S. S., Soares, M. J., Slivkoff-Clark, K. M., & James, A. P. (2016). Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome. Lipids in health and disease, 15(1), 169. https://doi.org/10.1186/s12944-016-0330-4
Irawati, Deasy, et al. "Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome." Lipids in health and disease vol. 15,1 (2016): 169. doi: https://doi.org/10.1186/s12944-016-0330-4
Irawati D, Mamo JC, Dhaliwal SS, Soares MJ, Slivkoff-Clark KM, James AP. Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome. Lipids Health Dis. 2016 Sep 29;15(1):169. doi: 10.1186/s12944-016-0330-4. PMID: 27686975; PMCID: PMC5043522.
Copy Download .nbib Format: NLM
Share it on

Lipids Health Dis. 2016 Sep 29;15(1):169. doi: 10.1186/s12944-016-0330-4.

Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome.

Lipids in health and disease

Deasy Irawati, John C L Mamo, Satvinder S Dhaliwal, Mario J Soares, Karin M Slivkoff-Clark, Anthony P James

Affiliations

  1. School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.
  2. Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
  3. Faculty of Medicine, Mataram University, West Nusa Tenggara, Indonesia.
  4. School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia. [email protected].
  5. Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia. [email protected].

PMID: 27686975 PMCID: PMC5043522 DOI: 10.1186/s12944-016-0330-4

Abstract

BACKGROUND: Subjects with metabolic syndrome (MetS) exhibit impaired lipoprotein metabolism and have an increased risk of cardiovascular disease. Although the risk is attributed primarily to the risk associated with individual components, it is also likely affected by other associated metabolic defects. Remnants of postprandial lipoproteins show potent atherogenicity in cell and animal models of insulin resistance and in pre-diabetic subjects with postprandial dyslipidemia. However, few studies have considered regulation of chylomicron remnant homeostasis in MetS per se. This study measured the plasma concentration in Caucasian men and women of small dense chylomicrons following fasting and explored associations with metabolic and anthropometric measures.

METHODS: A total of 215 Australian Caucasian participants (median age 62 years) were investigated. Of them, 40 participants were classified as having MetS. Apolipoprotein (apo) B-48, an exclusive marker of chylomicrons, metabolic markers and anthropometric measures were determined following an overnight fast.

RESULTS: The fasting apo B-48 concentration was 40 % higher in subjects with MetS than those without MetS. In all subjects, triglyceride (r = 0.445, P < 0.0005), non-HDL cholesterol (r = 0.28, P < 0.0005) and HDL cholesterol concentration (r = -0.272, P < 0.0005) were weakly associated with apo B-48 concentration. In subjects with MetS, the association of apo B-48 with triglyceride and non-HDL cholesterol was enhanced, but neither were robust markers of elevated apo B-48 in MetS (r = 0.618 and r = 0.595 respectively). There was no association between apo B-48 and HDL cholesterol in subjects with MetS.

CONCLUSION: This study demonstrates a substantial accumulation of pro-atherogenic remnants in subjects with MetS. We have shown that in a Caucasian cohort, the fasting plasma concentration of triglyceride or HDL/non-HDL cholesterol serves as poor surrogate markers of atherogenic chylomicron remnants. These findings suggest that subjects with MetS exhibit a chronic defect in chylomicron metabolism that is likely to contribute to their increased CV risk.

Keywords: Apolipoprotein B-48; Chylomicron; Metabolic syndrome

References

  1. Endocrine. 2016 Dec;54(3):588-601 - PubMed
  2. J Clin Lipidol. 2008 Aug;2(4):267-73 - PubMed
  3. Clin Biochem. 2003 Sep;36(6):421-9 - PubMed
  4. J Clin Invest. 1991 Dec;88(6):2059-66 - PubMed
  5. Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1595-600 - PubMed
  6. Atherosclerosis. 1996 Aug 2;124(2):221-35 - PubMed
  7. Eur J Clin Invest. 1998 May;28(5):379-84 - PubMed
  8. Eur Heart J. 2007 Apr;28(7):857-64 - PubMed
  9. Circulation. 2005 Aug 2;112(5):666-73 - PubMed
  10. J Atheroscler Thromb. 2009 Mar;16(1):12-20 - PubMed
  11. Int J Vasc Med. 2012;2012:784536 - PubMed
  12. Diabetes. 2006 May;55(5):1316-26 - PubMed
  13. J Biol Chem. 2002 Aug 30;277(35):31646-55 - PubMed
  14. Clin Chem Lab Med. 2003 Jun;41(6):792-5 - PubMed
  15. Exp Biol Med (Maywood). 2004 Jun;229(6):528-37 - PubMed
  16. Biochim Biophys Acta. 1996 May 20;1300(3):151-70 - PubMed
  17. J Clin Invest. 1993 Nov;92(5):2191-8 - PubMed
  18. Eur J Clin Invest. 2012 Jul;42(7):702-8 - PubMed
  19. Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26 - PubMed
  20. Clin Chim Acta. 2012 Jan 18;413(1-2):160-5 - PubMed
  21. Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):531-8 - PubMed
  22. Clin Biochem. 2000 Oct;33(7):549-55 - PubMed
  23. Clin Sci (Lond). 2004 Sep;107(3):233-49 - PubMed
  24. Clin Sci (Lond). 2000 Feb;98(2):183-92 - PubMed
  25. Circulation. 2009 Oct 20;120(16):1640-5 - PubMed
  26. Circulation. 1979 Sep;60(3):473-85 - PubMed
  27. Clin Chim Acta. 2008 Apr;390(1-2):38-43 - PubMed
  28. Coron Artery Dis. 1994 Aug;5(8):695-705 - PubMed
  29. Clin Chim Acta. 2005 Jan;351(1-2):115-20 - PubMed
  30. Atherosclerosis. 2005 Aug;181(2):345-51 - PubMed
  31. Atheroscler Suppl. 2015 Feb;17:12-6 - PubMed
  32. Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1357-63 - PubMed
  33. J Lipid Res. 2003 Jun;44(6):1256-62 - PubMed
  34. Coron Artery Dis. 1996 Mar;7(3):239-45 - PubMed
  35. J Atheroscler Thromb. 2009 Aug;16(4):517-22 - PubMed
  36. Curr Opin Lipidol. 2012 Aug;23(4):398-9 - PubMed
  37. J Lipid Res. 2012 Aug;53(8):1451-8 - PubMed
  38. Atherosclerosis. 2015 Nov;243(1):236-41 - PubMed
  39. Eur J Clin Invest. 2012 Sep;42(9):992-9 - PubMed
  40. Clin Biochem. 2009 Sep;42(13-14):1331-46 - PubMed
  41. Eur J Nutr. 2016 Jun;55(4):1503-13 - PubMed
  42. Curr Opin Lipidol. 2010 Jun;21(3):218-28 - PubMed
  43. Am J Med. 2006 Oct;119(10):812-9 - PubMed
  44. J Atheroscler Thromb. 2014;21(6):618-27 - PubMed

Publication Types